Moreover, our data reveal that the use of inhibitors of the METTL3/METTL14 complex may represent an effective therapy for killing CML cells that evade tyrosine kinase inhibition. This evidence concerns the gene METTL14 and chronic myelogenous leukemia, BCR-ABL1 positive.